Literature DB >> 17941650

Trafficking of preassembled opioid mu-delta heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by agonists.

Ahmed Hasbi1, Tuan Nguyen, Theresa Fan, Regina Cheng, Asim Rashid, Mohammad Alijaniaram, Mark M Rasenick, Brian F O'Dowd, Susan R George.   

Abstract

The cellular site of formation, Galpha-coupling preference, and agonist regulation of mu-delta opioid receptor (OR) heterooligomers were studied. Bioluminescence resonance energy transfer (BRET) showed that mu-deltaOR heterooligomers, composed of preformed mu and delta homooligomers, interacted constitutively in the endoplasmic reticulum (ER) with Galpha-proteins forming heteromeric signaling complexes before being targeted to the plasma membrane. Compared to muOR homooligomers, the mu-delta heterooligomers showed higher affinity and efficiency of interaction for Gz over Gi, indicating a switch in G-protein preference. Treatment with DAMGO or deltorphin II led to coregulated internalization of both receptors, whereas DPDPE and DSLET had no effect on mu-delta internalization. Staggered expression resulted in non-interacting mu and delta receptors, even though both receptors were colocalized at the cell surface. Agonists failed to induce BRET between staggered receptors, and resulted in internalization solely of the receptor targeted by agonist. Thus, mu-deltaOR heterooligomers form and preferentially associate with Gz to generate a signaling complex in the ER, and have a distinct agonist-internalization profile compared to either mu or delta homooligomers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17941650     DOI: 10.1021/bi701436w

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  42 in total

1.  Agonists at the δ-opioid receptor modify the binding of µ-receptor agonists to the µ-δ receptor hetero-oligomer.

Authors:  N Kabli; N Martin; T Fan; T Nguyen; A Hasbi; G Balboni; B F O'Dowd; S R George
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4.

Authors:  Thomas J LaRocca; Martina Schwarzkopf; Perry Altman; Shihong Zhang; Achla Gupta; Ivone Gomes; Zikiar Alvin; Hunter C Champion; Georges Haddad; Roger J Hajjar; Lakshmi A Devi; Alison D Schecter; Sima T Tarzami
Journal:  J Cardiovasc Pharmacol       Date:  2010-11       Impact factor: 3.105

Review 3.  Regulation of G protein-coupled receptor signaling by plasma membrane organization and endocytosis.

Authors:  Zara Y Weinberg; Manojkumar A Puthenveedu
Journal:  Traffic       Date:  2019-01-11       Impact factor: 6.215

Review 4.  Opioid-receptor-heteromer-specific trafficking and pharmacology.

Authors:  Richard M van Rijn; Jennifer L Whistler; Maria Waldhoer
Journal:  Curr Opin Pharmacol       Date:  2009-10-19       Impact factor: 5.547

5.  The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability.

Authors:  Shou-Pu Yi; Qing-Hong Kong; Yu-Lei Li; Chen-Ling Pan; Jie Yu; Ben-Qiang Cui; Ying-Fei Wang; Guan-Lin Wang; Pei-Lan Zhou; Li-Li Wang; Ze-Hui Gong; Rui-Bin Su; Yue-Hai Shen; Gang Yu; Kwen-Jen Chang
Journal:  Acta Pharmacol Sin       Date:  2017-05-15       Impact factor: 6.150

6.  Standard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective μ-δ agonists.

Authors:  Ajay S Yekkirala; Alexander E Kalyuzhny; Philip S Portoghese
Journal:  ACS Chem Neurosci       Date:  2009-11-25       Impact factor: 4.418

Review 7.  Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.

Authors:  Ivone Gomes; Wakako Fujita; Moraje V Chandrakala; Lakshmi A Devi
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

Review 8.  G Protein-Coupled Receptor Heteromers.

Authors:  Ivone Gomes; Mohammed Akli Ayoub; Wakako Fujita; Werner C Jaeger; Kevin D G Pfleger; Lakshmi A Devi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-22       Impact factor: 13.820

Review 9.  Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.

Authors:  Wakako Fujita; Ivone Gomes; Lakshmi A Devi
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 10.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.